Introduction
============

In only 6 centuries, the production and consumption of tobacco has been extended from the Americas to the rest of the world without respecting borders, cultures, or beliefs. During this period, tobacco consumption integrated naturally into different societies, such that about 80% of certain sectors of these populations have at least tried smoking ([@b74-copd-3-285]; [@b38-copd-3-285]).

Tobacco consumption is one of the greater pandemics of all time. Active smoking puts a patient at greater risk for developing chronic obstructive pulmonary disease (COPD) than any other single risk factor ([@b62-copd-3-285], [@b63-copd-3-285], [@b64-copd-3-285]). Of all the cases of COPD worldwide, 81.5%--90.0% can be attributed to a history of smoking ([@b62-copd-3-285], [@b63-copd-3-285], [@b64-copd-3-285]). COPD is often accompanied by other smoking-related comorbidities such as cancer, cardiovascular disease (CVD), and stroke ([@b64-copd-3-285]; [@b26-copd-3-285]). Other chronic diseases such as osteoporosis are also prevalent in patients with COPD ([@b7-copd-3-285]). In addition, COPD has been linked to increased relative risk of hospitalization for and mortality from CVD ([@b23-copd-3-285]; [@b59-copd-3-285]), especially in patients under 65 years of age ([@b59-copd-3-285]). Between COPD and other smoking-related diseases (eg, cancer and cardiovascular disease), smoking will eventually kill half of the current 1.25 billion smokers in the world ([@b68-copd-3-285]). Currently, smoking causes 5 million deaths annually ([www.paho.org](www.paho.org)) and these death tolls are predicted to reach 1 billion people in the next century ([@b26-copd-3-285]). These numbers will not be equally distributed throughout the entire world. Developed countries will experience 50% increases in tobacco-related deaths, whereas underdeveloped countries will see smoking-related deaths increase by 700% ([@b10-copd-3-285]; [@b26-copd-3-285]). By 2030, tobacco consumption will kill up to 10 million people every year ([@b44-copd-3-285]), and 70% of those deaths will occur in developing countries ([@b42-copd-3-285]). Poverty and lack of education ([@b27-copd-3-285]; [@b21-copd-3-285]), and promotion of smoking in women ([@b24-copd-3-285]) and adolescents ([@b20-copd-3-285]) are key factors contributing to the exponential growth of the tobacco pandemic.

When faced with these issues, a few questions prevail. What makes tobacco consumption a universal phenomenon without geographic, idiomatic, or cultural limits? How, in only a few centuries, did tobacco consumption spread throughout the entire world from Latin America? Why does this pandemic continue to remain ignored, diminished, and disqualified, in spite of considerable evidence from more than a half century of research about the harmful effects of tobacco?

Tobacco production
==================

The 2nd edtion of The Tobacco Atlas lists 20 Latin American countries that seed and cultivate tobacco ([Table 1](#t1-copd-3-285){ref-type="table"}) ([@b26-copd-3-285]). Currently, 5 out of the 25 largest tobacco producers in the world are countries of this region (Brazil, Argentina, Cuba, Dominican Republic, and Colombia) ([@b65-copd-3-285]). Brazil stands out as the second largest worldwide producer of tobacco, generating 928,300 tonnes annually, and as the top tobacco exporter (US\$1,052 million during 2003) ([@b26-copd-3-285]). At the time of the data used in the 2nd edition of The Tobacco Atlas, Argentina was the eighth largest worldwide producer (118,000 tonnes/year) ([@b26-copd-3-285]). Now with a production of 161,000 tonnes/year (2006), however, it would occupy fifth place among the countries listed in The Tobacco Atlas. Overall in Latin America, tobacco production between 1995 and 2000 grew 29.5%. During the same period, the amount of land used to cultivate tobacco increased by 10.3% and the yields per hectare improved by 17.3% ([@b65-copd-3-285]).

These data underscore the economic impact of tobacco production in Latin America, which presents a challenge for the next generations who will have to promote other strategies to break free from the economic dependence on tobacco (eg, substitution of plantations).

Tobacco pricing
===============

Local economies determine how individual countries and tobacco producers price cigarettes. This is why, for example, Venezuela and Paraguay have the lowest worldwide prices of premium cigarettes like Marlboro (less than US\$1 for a pack of 20) ([@b26-copd-3-285]). In Argentina, Brazil, Peru, Ecuador, Colombia, Mexico, Costa Rica, Panama, and Guatemala, prices oscillate between US\$1 and US\$1.99. In Chile, and Uruguay the cost varies from US\$2 to US\$2.9 ([@b26-copd-3-285]). In addition, alternative brands of cigarettes may sell at much lower prices, such as in Argentina, where the prices of these cheap brands do not surpass US70 cents.

These low prices, in conjunction with underdeveloped conditions of much of Latin America, foster more tobacco consumption and constantly increase the total number of smokers, especially among adolescents and women ([@b26-copd-3-285]). Furthermore, tobacco production is not associated with a higher index of wellbeing. The major tobacco-producing provinces in Argentina, for example, show the smallest index of human development, the biggest percentage of insufficient basic needs, the highest illiteracy rate of the country, and the shortest life expectancy ([@b30-copd-3-285]). The losses generated by smoking-related diseases widely surpass the economic gains that the industry produces.

As of 2003, Argentina spends US\$1.4 million annually on the treatment of tobacco-related pathologies ([@b8-copd-3-285]). This represents 15.5% of the total health care costs and these costs were not compensated by revenues from tobacco taxes (ie, US\$806 million in 2003) ([@b31-copd-3-285]). In Colombia, the losses from tobacco-related premature mortality and disease-related disability are 4 times greater than the income generated by tobacco in the economy of the country ([@b48-copd-3-285]).

One strategy to wean countries of their economic dependence on tobacco production would be to enact policies that raise the price of cigarettes. Not only would this increase the amount of taxes collected for each pack sold, but it may also reduce the prevalence of smoking ([@b67-copd-3-285]). A 10% rise in the price of a pack of cigarettes, in high income countries, has been linked to a potential 4% decrease in smoking and in low to middle income countries; this benefit doubles to an 8% drop in smoking levels ([@b67-copd-3-285]). Moreover, the effects of such a price increase is even more pronounced in adolescent smokers, with a 10% price increase yielding an estimated 14%--15% fall in smoking ([@b13-copd-3-285], [@b12-copd-3-285]). However, for price increase to be an effective measure, illegal tobacco smuggling would need to be controlled.

Tobacco smuggling
=================

In Latin America, tobacco smuggling is a serious problem ([@b25-copd-3-285]). A considerable circuit of illegal trade exists from Aruba (Dutch Antilles) to many Caribbean ports and Colombia ([@b1-copd-3-285]). Also since 2002, the illegal pathway from Paraguay to Argentina has grown considerably and today comprises 20% of the whole tobacco market ([@b35-copd-3-285]). Although Paraguay exports 2 billion cigarettes legally each year, its actual production is near 40 billion cigarettes. Since the country consumes 3 billion cigarettes a year, the final destinations of 35 billion cigarettes is unknown ([@b35-copd-3-285]). Although in 2006, Uruguay Customs seized 24 million illegal cigarettes worth US\$1 million, most of those cigarettes had come from Argentina and Paraguay ([@b52-copd-3-285]). Of course, not all the illegal cigarettes in Uruguay come from other countries; in fact, 80% of the cigarettes produced in Uruguay for export return to the country to be sold illegally ([@b52-copd-3-285]). Other Latin American countries also are exposed to illegal smuggled cigarettes. Data from the Finances Secretary of Brazil, for example, indicate that falsification, illegal manufacturing, and smuggled products represented 30% of the total number of consumed cigarettes in 2005 ([@b17-copd-3-285]). Also, 14% of the cigarettes sold in Colombia in 2004 were counterfeit or smuggled ([@b2-copd-3-285]). Stronger measures throughout Latin America must be implemented to bring a halt to this illegal cigarette trade, not only to prevent the economic losses due to uncollected taxes, but also to prevent its people from being exposed to cheap, unregulated cigarettes that further encourage smoking.

Prevalence of tobacco consumption
=================================

Data linked to the incidence of tobacco consumption in the region are few, and frequently controversial. According to the 2nd ed of The Tobacco Atlas, the annual per person cigarette consumption in Latin American countries ranges between 500 and 1500 cigarettes per year ([@b26-copd-3-285]), with the exception of Ecuador, Peru, Bolivia, and Paraguay, where the annual per person cigarette consumption is less than 500 cigarettes per year ([@b58-copd-3-285]; [@b15-copd-3-285]; [@b61-copd-3-285]; [@b26-copd-3-285]).

Between 8% and 10% of the smokers of the world (ie, more than 120 million) live in Latin America ([@b26-copd-3-285]), and thus, the smoking rates in Latin America are high ([Table 2](#t2-copd-3-285){ref-type="table"}). Half of these smokers will die prematurely of a tobacco-dependent disease ([@b68-copd-3-285]).

Tobacco use among adolescents
=============================

Latin American data compiled from the Pan American Health Organization (PAHO) and the WHO show that 13.16% of young people between 15 and 18 years old are smokers ([@b45-copd-3-285]). The following countries have the highest youth smoking rates of the region: Chile (39.2%), Colombia (33.4%), Mexico (27.1%), Argentina (25.8%), and Uruguay (22.9%). At the other extreme, Cuba (8.8%), Dominican Republic (5.8%), and Venezuela (8.4%) possess the lowest youth smoking rates of the region ([Table 2](#t2-copd-3-285){ref-type="table"}) (Warren et al 2008). Although there are significant variations between countryside (lower smoking prevalences) and urban zones (higher smoking prevalences), the rates vary between 20% and over 70%, showing that use of tobacco is a common behavior among young Latin American people ([@b11-copd-3-285]). The addictive power of nicotine, the genetic predisposition of each "experimenter", and other personal (ie, social and psychological) factors will influence how many of these young people become smokers in the long term.

Tobacco use among females
=========================

The incidence of tobacco consumption in adult women (≥15 years) varies by Latin American region and usually the data differ according to the source researched. However, Latin America is a good example of the worldwide female trend of increasing tobacco addition ([Table 2](#t2-copd-3-285){ref-type="table"}). A country that clearly exhibits this trend is Chile, with 34.9% of women being smokers in the 2005 survey ([@b45-copd-3-285]). The female smoking trends in Argentina (22.6%--30.7%), Bolivia (28.6%), Cuba (26.5%), Uruguay (25.1%), and Venezuela (23.3%) are also worrisome. The country with the smallest frequency of female adult smokers is Guatemala with a rate of 0.9% on the 2005 survey ([@b45-copd-3-285]).

The numbers of females who are smokers are even more disquieting when analyzing the population of young women (15--18 years old) ([Table 2](#t2-copd-3-285){ref-type="table"}). Colombia is the country with highest prevalence, reaching 31.0%, followed by Chile (27.5%), Ecuador (27.2%), Mexico (26.3%), and Nicaragua (25.6%). The lowest levels of tobacco consumption in this population are in Venezuela (6.0%), the Dominican Republic (7.3%), and Brazil (9.1%) (Warren et al 2008).

These data foretell a dire impact that tobacco-related diseases will have on the health of Latin American women, if smoking is not mediated with strong prevention measures and treatments against tobacco addiction. This is, and will continue to be, a big challenge for Latin America.

Strategies for change
=====================

The world is beginning to witness a great sociocultural change linked to tobacco. Nicotine addiction is more extensive than ever in human history and its serious consequences are universally recognized. The tobacco pandemic has necessitated a movement without precedent, in which nations from around the world must dictate policies to control its use and the consequences from it.

The WHO has warned about the dangers of tobacco and has been working for several years towards the establishment of changing strategies ([@b70-copd-3-285]). To this end, and after intense negotiations, 168 nations signed the Framework Convention on Tobacco Control (FCTC), which is the first international health pact that establishes the basis of a synchronized and unified fight of all of these countries against tobacco consumption ([@b69-copd-3-285]). The FCTC has the objective "to protect present and future generations from the devastating health, social, environmental and economic consequences of tobacco consumption and exposure to tobacco smoke by providing a framework for tobacco control measures to be implemented by the Parties at the national, regional and international levels in order to reduce continually and substantially the prevalence of tobacco use and exposure to tobacco smoke" ([@b36-copd-3-285]; [@b69-copd-3-285]).

The FCTC took effect February 27, 2005, and since this date, it has been ratified by 148 countries, including almost all the Latin American countries, with the exception of Argentina. In Argentina, the FCTC continues to be disputed by the Executive Power, which favors the FCTC, and the Legislative Power, where the representatives of the tobacco provinces refuse to accept the policies to the control tobacco. While each nation supporting the FCTC passes legislation to combat tobacco consumption, humanity as a whole must become aware of the magnitude of the problem. In Latin America, clinicians should make a serious effort to discourage smoking through patient education.

Role of health care professionals
=================================

One of the difficulties in controlling this epidemic is the lack of knowledge and training by doctors in treating tobacco addiction ([@b41-copd-3-285]; [@b73-copd-3-285]; [@b28-copd-3-285], [@b29-copd-3-285]; [@b16-copd-3-285]). Each member of the health team has a fundamental role in the treatment. Nurses, social workers, administrators, directors, primary care physicians, and specialist doctors must know that tobacco consumption is a disease. All of them should promote an open atmosphere of a health treatment to compel people to stop smoking by advising and assisting in the treatment process with a level of intervention appropriate for each particular case ([@b32-copd-3-285]).

When reviewing information about tobacco addiction that medical students from 18 Latin America countries receive, the conclusion was that only 6 countries offer tobacco education, 2 offer partial education, and 10 do not offer tobacco education at all ([Table 4](#t4-copd-3-285){ref-type="table"}) ([@b45-copd-3-285]). In Argentina, for example, less than 30% of surveyed doctors acknowledged having received information on the subject ([@b53-copd-3-285]; [@b72-copd-3-285]; [@b74-copd-3-285]; [@b3-copd-3-285]; [@b38-copd-3-285]). Thus, the introduction of systematic education in tobacco consumption at medical schools needs to be implemented to contribute to the cultural change of health professionals.

Doctors must position themselves to be leaders in the fight against tobacco. They must get involved and fulfill their functions properly within their sphere of responsibilities. This is the model followed by countries that have experienced success in controlling the tobacco epidemic ([@b53-copd-3-285]; [@b72-copd-3-285]).

A lot of evidence indicates that health professionals who smoke are less active in the fight against tobacco consumption. They may have less confidence in their own advice; they may not believe in preventive intervention or in smoking cessation; and they may even lack trust in the treatments against nicotine ([@b53-copd-3-285]; [@b3-copd-3-285]; [@b38-copd-3-285]). Another issue is that the frequency of tobacco consumption among Latin American health professionals is similar to the levels of the general population; only in Brazil and El Salvador are significant differences observed, with indices up to \~7% ([@b34-copd-3-285]; [@b54-copd-3-285]; [@b6-copd-3-285]; [@b37-copd-3-285]; [@b3-copd-3-285]; [@b38-copd-3-285]; [@b26-copd-3-285]; [@b71-copd-3-285]).

Initiating policies to control tobacco consumption -- in conjunction with the availability of successful medical alternative treatments for nicotine addiction -- will increase the demand for smoking cessation programs. For these reasons, education and training of health teams in general, and of doctors especially, is indispensable. These health professionals can, in turn, assist smokers using therapeutic resources with proven ability, without fear of discrediting themselves. Furthermore, smoking cessation clinics of trained health professionals could be established where doctors could refer smokers for additional support and treatment.

In this context, the tobacco cessation guidelines adapted to each country, and in particular to the Latin America regions, are indispensable instruments to regulate treatments and to influence health professionals to be an active part of the tobacco cessation process. The guidelines must be based on the maximum evidence available and be agreed upon by a group of local leaders following a formal and rigorous consensus on methodology. A good example is the Argentinean treatment guidelines for tobacco addiction ([@b31-copd-3-285]), for which planning and development were based on the NICE recommendations (National Institute of Clinical Excellence) ([@b39-copd-3-285]), and on the recommendations of AGREE (Appraisal of the Guidelines Research and Evaluation) ([@b5-copd-3-285]). Their main objectives are to increase the percentage of smokers who stop smoking, ensure that all health workers have the basic tools to facilitate the process of recovery from tobacco dependency, offer basic recommendations based upon the best evidence of efficacy and cost effectiveness of treatments to stop smoking, and adapt the national evidence to the local level in order to increase the feasibility and applicability of the recommendations.

Brazil, Costa Rica, Mexico, Panama, and Uruguay also have national guidelines, and are participating in a project to expand Latin American guidelines with the consensus of all the nations that comprise the region.

Available pharmacological treatments
====================================

Nicotine replacement therapies (NRT) may double the odds of successful abstinence from smoking compared to placebo (continuous abstinence from 6--12 months, pooled studies N =39,503; odds ratio \[OR\] =1.77; 95% confidence interval \[CI\]: 1.66--1.88) ([@b60-copd-3-285]). NRT in the form of gums and patches are available over the counter in almost all Latin American countries. In addition, Mexico has a nicotine oral inhalant ([@b55-copd-3-285]). Only in some countries -- such as Chile, Peru, and Venezuela -- is a medical prescription necessary to buy NRTs ([@b45-copd-3-285]). Recently, the nasal spray became available in Argentina, but only under medical prescription. The most commonly observed adverse events (AEs) associated with NRTs includes pain in the jaw; gastrointestinal problems, hiccoughs, or orodental damage (gum); local skin irritation (patch); irritation or burning of the mouth or throat and coughing (inhaler); irritated or runny nose (nasal spray) ([@b60-copd-3-285]).

A 2 mg box of NRT gum (ie, a 3-day supply) costs between US\$10 and US\$16 in Colombia, Brazil, Uruguay, and Argentina ([www.kairosweb.com](www.kairosweb.com)). This price represents between 5% and 12% of the minimum salary. A box of NRT gum costs the same as 9 packs (of 20 cigarettes) of the cheapest brand in Argentina, 10 packs in Uruguay, 12 in Colombia, and 21 in Brazil ([www.kairosweb.com](www.kairosweb.com)). The gap between the price of smoking cessation medication and cigarette packs is bigger in Latin America than in Western Europe, where medicines are proportionally more accessible and cigarettes are significantly more expensive. The recommended dosing schedules vary by the type of NRT and needs of the smokers, but can range from 12 weeks to 6 months or more ([@b45-copd-3-285], [@b50-copd-3-285]; [@b18-copd-3-285]).

The medication bupropion is available in practically all the countries of the region and always requires a medical prescription ([@b45-copd-3-285]). Bupropion approximately doubles the odds of successful smoking cessation over placebo at 6 months or greater (pooled studies N = 6433; OR = 2.06; 95% CI: 1.77--2.40) ([@b22-copd-3-285]). The most commonly observed AEs include insomnia, dry mouth, headache, and jitteriness ([@b22-copd-3-285]). As an antidepressant drug, bupropion is partially financed by many Latin American public health systems or private medical systems and its cost is usually lower than NRT. For example, a package of 30 tablets (ie, a 15-day supply) costs US\$13 in Uruguay and US\$18 in Argentina ([www.kairosweb.com](www.kairosweb.com)). The recommended dosing regimen is 150 mg twice daily for 7--12 weeks ([@b19-copd-3-285]).

The medication varenicline became available beginning March/April of 2007 in Uruguay, Mexico, Chile, Brazil, and Argentina. Varenicline is the first non-nicotine pharmacotherapy developed for smoking cessation and may triple the odds of smoking cessation versus placebo (at 1 year, pooled studies N = 1082; OR = 3.22; 95% CI: 2.43--4.27) ([@b9-copd-3-285]). The most commonly reported treatment-emergent AEs with varenicline are nausea, insomnia, headache, and abnormal dreams ([@b9-copd-3-285]). The average cost of varenicline is US\$57 to US\$60 for a 2-week supply ([www.kairosweb.com](www.kairosweb.com)) and the recommended treatment period is 12 weeks ([@b51-copd-3-285]).

Presently, only Brazil and Uruguay have national laws to control tobacco consumption and offer free medication as part of a public health policy. In Argentina, some Municipal Hospitals in Buenos Aires provide free treatments in the clinics for smoking cessation. According to the PAHO ([www.paho.org](www.paho.org)), almost all the Latin American countries have doctor's offices for smoking cessation, although the coverage is different between countries. Countries such as Brazil, Uruguay, Mexico, and Argentina have national tobacco control programs with specific goals that include health professionals with qualification for smoking cessation treatments. At the same time other countries still have not implemented these tools.

Drugs for the treatment of tobacco addiction are cost effective. It will be the responsibility of the health administrators, public and private, to fund tobacco cessation programs. These prevention measures will have a positive impact on the health of smokers.

Conclusions
===========

Tobacco consumption is an *addiction*, accepted worldwide as a *natural behavior*, entrenched in *established multi-cultural bases*, propagated by *advertising*, and encouraged as *a rapid wealth generator*. The tobacco consumption problem is complex and involves social, cultural, economic, and public health aspects. Fighting the use of tobacco is a society's responsibility, which could be achieved through the combined efforts of societal institutions, governments, educators, and leaders.

To change the prognosis of the dangers of tobacco in the future, certain actions must be taken. These actions include: education, at all levels, about the real consequences of tobacco consumption; activation of public health policies to control tobacco consumption in order to protect minors and nonsmokers; commitment of the health professionals in general and doctors specifically; and participation of society as a whole. This is a pending and inescapable commitment for Latin America. Latin American territories have the most vulnerable conditions that expose them to the consequences of the tobacco epidemic. Latin America encompasses a group of countries still in development. In the majority of these countries, tobacco plantations are prevalent and tobacco products are commercialized ([@b65-copd-3-285]; [@b26-copd-3-285]). Thus, the tobacco industry exercises powerful political influences for tobacco growth, such as eluding restrictions and accommodating tobacco production ([@b56-copd-3-285]; [@b71-copd-3-285]). Smoking has integrated into the culture and customs of these countries, most of which are just now beginning tobacco control policies.

The harm caused by the tobacco consumption, the addictive characteristics of the disease, and the consequences of environmental tobacco smoke have spread greatly just in the last few years. Smoking tobacco is cheap and therefore within reach of almost all of the Latin American population. Health professionals also exhibit similar demographics of tobacco consumption to the population that they should help. They are generally poorly educated and trained on the topic, lacking knowledge about the prescribing and utility of available smoking cessation pharmacological treatments ([@b41-copd-3-285]; [@b33-copd-3-285]; [@b28-copd-3-285]; [@b53-copd-3-285]; [@b73-copd-3-285]; [@b72-copd-3-285]; [@b54-copd-3-285]; [@b6-copd-3-285]; [@b16-copd-3-285]; [@b37-copd-3-285]; [@b74-copd-3-285]; [@b3-copd-3-285]; [@b45-copd-3-285]; [@b38-copd-3-285]; [@b26-copd-3-285]; [@b29-copd-3-285]; [@b71-copd-3-285]).

Considering these conditions, it can be speculated that tobacco consumption in Latin America will continue increasing in the future, especially affecting women and young people. However, the emergence of control policies, expansion of knowledge, and new therapeutic possibilities inspire hope. Therefore, all action towards tobacco control is anticipated and welcome. The commitment to the FCTC, the policies for tobacco control, and the creation of health reforms supporting and promoting tobacco cessation will be instruments of extraordinary value in this fight. For Latin America, it is urgent to educate health professionals to be part of the tobacco cessation effort, so that -- with the arrival of new drugs and the application of better strategies adapted to their customs -- more patients can stop smoking.
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###### 

Tobacco cultivation in Latin America

  Country              Hectares      Tonnes
  -------------------- ------------- ---------------
  Argentina            66,000        118,000
  Bolivia              1,060         100
  Brazil               469,678       928,300
  Chile                2,970         9,300
  Colombia             13,000        28,000
  Costa Rica           117           200
  Cuba                 33,942        34,500
  Ecuador              4,300         8,000
  El Salvador          600           1,100
  Guatemala            9,232         20,500
  Haiti                450           500
  Honduras             1,170         5,200
  México               11,461        21,900
  Nicaragua            1,395         2,200
  Panama               1,250         2,300
  Paraguay             8,268         16,500
  Peru                 1,050         12,200
  Dominican Republic   14,000        18,000
  Uruguay              900           3,000
  Venezuela            3,246         6,100
  **Total**            **644,089**   **1,235,900**

644,089 hectares in Latin America are destined to seedtime, reaching a production of 1,235,900 tonnes per year. Data derived from the 2006 Tobacco Atlas ([@b26-copd-3-285]).

###### 

Prevalence of smoking in Latin America

  Country                                                        Population^†^   Male (%)                                         Female (%)   Total (%)
  -------------------------------------------------------------- --------------- ------------------------------------------------ ------------ ------------------------------------------------
  Argentina[a](#tfn3-copd-3-285){ref-type="table-fn"}            36,772,000      28.9                                             22.6         25.8
  Bolivia[a](#tfn3-copd-3-285){ref-type="table-fn"}              8,814,000       31.0                                             28.6         29.9
  Brazil[a](#tfn3-copd-3-285){ref-type="table-fn"}               179,596,000     21.4                                             12.7         16.9
  Chile[a](#tfn3-copd-3-285){ref-type="table-fn"}                15,774,000      39.0                                             34.9         37.0
  Colombia[b](#tfn4-copd-3-285){ref-type="table-fn"}             44,584,000      26.8                                             11.3         18.9
  Costa Rica[a](#tfn3-copd-3-285){ref-type="table-fn"}           4,005,000       2.5                                              3.5          3.0
  Cuba[a](#tfn3-copd-3-285){ref-type="table-fn"}                 11,326,000      43.1                                             26.5         34.8
  Dominican Republic[a](#tfn3-copd-3-285){ref-type="table-fn"}   8,739,000       15.3                                             11.1         13.2
  Ecuador[a](#tfn3-copd-3-285){ref-type="table-fn"}              13,008,000      7.9                                              1.9          4.8
  El Salvador^c^                                                 6,533,000       42.1                                             14.8         N/A[f](#tfn7-copd-3-285){ref-type="table-fn"}
  Guatemala[a](#tfn3-copd-3-285){ref-type="table-fn"}            12,500,000      7.7                                              0.9          4.1
  Haiti[d](#tfn5-copd-3-285){ref-type="table-fn"}                8,440,000       10.7                                             8.6          9.5
  Honduras[b](#tfn4-copd-3-285){ref-type="table-fn"}             6,969,000       36.0                                             11.0         24.0
  Mexico[a](#tfn3-copd-3-285){ref-type="table-fn"}               102,291,000     12.5                                             4.5          8.3
  Nicaragua[e](#tfn6-copd-3-285){ref-type="table-fn"}            5,480,000       32.9[f](#tfn7-copd-3-285){ref-type="table-fn"}   7.8          21.0[f](#tfn7-copd-3-285){ref-type="table-fn"}
  Panama[b](#tfn4-copd-3-285){ref-type="table-fn"}               2,984,000       19.7                                             6.1          12.9
  Paraguay[a](#tfn3-copd-3-285){ref-type="table-fn"}             5,643,000       23.6                                             7.4          15.5
  Peru[b](#tfn4-copd-3-285){ref-type="table-fn"}                 27,148,000      52.5                                             17.8         33.8
  Uruguay[a](#tfn3-copd-3-285){ref-type="table-fn"}              3,380,000       35.0                                             25.1         29.8
  Venezuela[a](#tfn3-copd-3-285){ref-type="table-fn"}            25,674,000      26.7                                             23.3         25.0

Data were collected from:

The PATIOS online database ([@b45-copd-3-285]).

2nd edition of The Tobacco Atlas of the American Cancer Society ([@b26-copd-3-285]). ^c^Comisión Salvadoreña Antidrogas (Antidrug Commission of El Salvador) (Pan American Health Organization).

Narcotics Awareness and Education Project ([@b40-copd-3-285]).

Central American Diabetes Initiative ([@b43-copd-3-285]).

N/A, not available.

###### 

Prevalence of smoking adolescents in Latin America

  Country              Year   Boys (%)   Girls (%)   Total (%)
  -------------------- ------ ---------- ----------- -----------
  Argentina            2003   21.9       17.2        25.8
  Bolivia              2003   16.3       20.3        12.0
  Brazil               2005   12.3       9.1         12.9
  Chile                2003   33.9       27.5        39.2
  Colombia             2001   32.2       31.0        33.4
  Costa Rica           2002   16.4       15.7        16.8
  Cuba                 2004   10.0       11.2        8.8
  Dominican Republic   2004   6.6        7.3         5.8
  Ecuador              2001   20.5       27.2        12.6
  El Salvador          2003   14.0       18.4        10.9
  Guatemala            2002   14.3       17.3        11.2
  Haiti                2005   17.6       17.2        17.7
  Honduras             2003   14.2       14.4        14.1
  Mexico               2005   27.1       26.3        27.1
  Nicaragua            2003   21.2       25.6        17.4
  Panama               2002   13.2       14.7        11.1
  Paraguay             2003   19.1       19.2        18.5
  Peru                 2003   19.2       20.8        17.0
  Uruguay              2007   20.2       16.4        22.9
  Venezuela            1999   7.4        6.0         8.4

Data were derived from The Global Youth Tobacco Survey (Warren et al 2008).

###### 

Tobacco education in medical schools

  Country              Year   Tobacco education      Date received
  -------------------- ------ ---------------------- ---------------
  Argentina            2002   In some universities   8/2002
  Bolivia              2002   No                     8/2002
  Colombia             2002   No                     9/2002
  Ecuador              2002   No                     7/2002
  Peru                 2002   Yes                    7/2002
  Venezuela            2002   No                     8/2002
  Costa Rica           2002   Yes                    7/2002
  El Salvador          2006   In some universities   1/2006
  Guatemala            2002   No                     7/2002
  Honduras             2002   Yes                    12/2002
  Nicaragua            2002   No                     8/2002
  México               2002   Yes                    8/2002
  Brazil               2003   No                     7/2003
  Chile                2002   No                     7/2002
  Paraguay             2002   Yes                    8/2002
  Uruguay              2002   No                     8/2002
  Dominican Republic   2003   No                     6/2003

Data were compiled form the Pan American Health Organization ([@b45-copd-3-285]).
